5. 复发转移乳癌的治疗指南Metastatic Breast CancerER / PR- or
Symptomatic Visceral or
Hormone RefractoryER / PR+ or Bone,
Soft Tissue Only or
Asymptomatic VisceralHormone Therapy
Multiple Lines Until ResistanceFirst-line Metastatic Chemotherapy*Salvage Chemotherapy
Multiple LinesBest Supportive Care* With trastuzumab for patients who are HER-2 neu overexpressers.
5 Clinical Practice Guidelines in Oncology. Breast Cancer 2006 (V2):23,36.
30. 治疗方案GP1 GEM 1250 mg/m2 D1+8
P 175 mg/m2 as 3-h inf D1
GP2 GEM 1000 mg/m2 D1+8
P 100 mg/m2 as 1-h inf D1+8
GD GEM 1000 mg/m2 D1+8
D 40 mg/m2 as 1-h inf D1+8
Repeated every three weeks
Maximum number of cycles allowed by protocol, 8分组
31. 基线情况 GP1 GP2 GD Total
(N=72) (N=67) (N=65) (N=204)
Age (years)
Median 48 47 48 48
Range 29-72 23-71 20-77 20-77
KPS
Mean 88 88 89 88
Range 70-100 70-100 70-100 70-100
32. 基线情况 (%) GP1 GP2 GD Total
(N=72) (N=67) (N=65) (N=204)
Dominant site of disease
Visceral 71 72 68 70
Liver 32 42 32 35
Bone 8 9 8 8
Soft tissue 21 19 25 22
Number of disease sites
1 24 19 14 19
2 28 27 34 29
3 49 54 52 52
33. 初期治疗 (%) GP1 GP2 GD Total
(N=72) (N=67) (N=65) (N=204)
Anthracyclines 100 99 100 99
For MBC (+/-adj a) 39 56 45 47
Taxanes (adj) 0 0 1.5 0.5
Other regimens 32 37 25 31
Endocrine therapy 35 45 43 41
For MBC (+/-adj) 24 31 35 30
a Includes neo-adjuvant
34. 有效率 (%) GP1 GP2 GD Total
(N=72) (N=67) (N=65) (N=204)
CR 4.2 6.0 4.6 4.9
PR 44.4 46.3 47.7 46.1
RR (%) 48.6 52.2 52.3 51.0
SD 18.1 19.4 10.8 17.2
PD 20.8 19.4 10.8 17.2
Not donea 9.7 4.5 7.7 7.4
Unknown 2.8 4.5 6.2 4.4
a Study therapy discontinued before first response assessment
35. 肿瘤进展时间 GP1 GP2 GD Total
TTP (ms) 7.5 7.0 7.4 7.1
95% CI 6.1-8.2 4.9-8.2 6.1-8.0 6.5-7.8
39. G-CSF and Antibiotics (% Patients) GP1 GP2 GD Total
N=72 N=68 N=68 N=208
G-CSF a 10 9 19 12
(Therapeutic)
ABs, total 46 41 68 51
ABs, IV 15 15 35 22
a Prophylactic use of G-CSF was not allowed
40. Blood Transfusions (%) GP1 GP2 GD Total
N=72 N=68 N=68 N=208
Whole blood 1 7 10a 6
RBC 4 1 18b 8
Platelets 1 3 0 1
a P = 0.0625 b P = 0.0009
41. Cycle Number GP1 GP2 GD Total
Total 399 382 403 1184
Per patient
Median 7 6 7 7
Range 1-8 1-8 1-8 1-8
51. 双周多西紫杉醇+吉西他滨新辅助治疗Ⅱ、Ⅲ期乳腺癌:Ⅱ期临床研究
Estévez LG, Sánchez‐Rovira P, Dómine M, León A, Calvo I, Jaén A, Casado V, Rubio G, Díaz M, Miró C, Lobo F, Carrasco E, Casillas M, San Antonio B.Fundación Jiménez Díaz, Madrid, Spain. Clin Transl Oncol. 2007 May;9(5):317‐22.